01877.HK
Shanghai Junshi Biosciences Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 18.22
+0.61%Year over year
Reported trailing growth
- Revenue
- +28.9%
- EBITDA
- +52.8%
- EBIT
- +46.4%
- EPS
- +62.7%
- Free cash flow
- +32.9%
- Operating cash flow
- +76.1%
Forward estimates
Based on analyst estimates
- Revenue
- -68.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +18.7%
- EBITDA
- +35.9%
- EBIT
- +32.1%
- Net income
- +33.5%
- EPS
- +35.4%
- Free cash flow
- +42.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026